Avacopan: all 22 studies that test it

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeRecruitingNCT07556484Phase 1
• Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney InvolvementNot yet recruitingNCT07373262Phase 3
• TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With PolyangiitisRecruitingNCT07176546Phase 2/3
• Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)RecruitingNCT06676579Phase 2
• Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated VasculitisRecruitingNCT06611696Phase 4
• A Study to Evaluate Avacopan in Participants With ANCA-associated VasculitisRecruitingNCT06072482Phase 4
• A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)CompletedNCT06468826Phase 1Results posted
• Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)CompletedNCT03852472Phase 2Results posted
• Controlled Trial Evaluating Avacopan in C3 GlomerulopathyCompletedNCT03301467Phase 2Results posted
• A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated VasculitisCompletedNCT02994927Phase 3Results posted
• Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS BlockadeCompletedNCT02384317Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated VasculitisCompletedNCT01363388Phase 2Results posted
• Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.Active, not recruitingNCT06321601Phase 3
• Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of SimvastatinCompletedNCT06207682Phase 1
• A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy ParticipantsCompletedNCT06004960Phase 1
• A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant MedicationsCompletedNCT06004947Phase 1
• A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic ImpairmentCompletedNCT06004934Phase 1
• A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy ParticipantsCompletedNCT05988034Phase 1
• A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168CompletedNCT05988021Phase 1
• A Study of CCX168 in Japanese and Caucasian Healthy Adult MalesCompletedNCT05988008Phase 1
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy ParticipantsCompletedNCT05984251Phase 1
• Complement Inhibition in aHUS Dialysis PatientsTerminatedNCT02464891Phase 2

← Avacopan overview